周一夜盘，生物技术公司Sarepta Therapeutics(SRPT)股价上涨5.01%，但这一反弹仅是部分修复了该公司当日早些时候遭受的重创。
据报道，Sarepta Therapeutics周一盘中一度暴跌超过47%，创下自2016年6月以来的最低价。暴跌原因是公司披露了与其杜氏肌营养不良症治疗药物Elevidys相关的第二例急性肝衰竭死亡案例。这一消息引发了市场对公司基因疗法安全性的担忧。
面对这一重大安全事件，Sarepta Therapeutics采取了一系列应对措施，包括暂时暂停对非行走患者的治疗药物发货，同时评估增强的免疫抑制方案。尽管如此，多家投资银行仍下调了对该公司的评级和目标价，反映出分析师对公司短期前景的担忧。
夜盘的小幅反弹可能反映了部分投资者认为股价超跌，但鉴于基因疗法安全性问题的严重性，Sarepta Therapeutics仍面临重大挑战。投资者将密切关注公司后续的安全性数据和监管机构的反应。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.